Mon.Aug 19, 2024

article thumbnail

DeepCure links with Leeds Institute to bring AI-based RA drug to clinic  

Pharmaceutical Technology

The partners will conduct a study using blood samples and joint biopsies from various patient subgroups, focusing on those resistant to current treatments.

Drugs 130
article thumbnail

As Bristol Myers’ schizophrenia drug nears approval, AbbVie and others hope to provide competition

Bio Pharma Dive

A new wave of antipsychotics could improve patient adherence. The race to corner this large projected market is already getting tight.

Marketing 295
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Eli Lilly acquires Morphic in IBD portfolio expansion

Pharmaceutical Technology

Eli Lilly has concluded the acquisition of Morphic Holding at $57 per share, bolstering its inflammatory bowel disease portfolio.

264
264
article thumbnail

Study Finds Humans Age Faster at 2 Sharp Peaks – Here’s When to Expect Them

AuroBlog - Aurous Healthcare Clinical Trials blog

The progress of a human being through life might be thought of as a mostly gradual succession of changes from the ovum to the grave. But if you wake up one morning, look in the mirror, and wonder when you suddenly grew so much older, you may not be imagining things.

Research 239
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Sound Pharmaceuticals plans to stick with WuXi amid BIOSECURE Act rumblings

Pharmaceutical Technology

Looking to potentially market their flagship drug SPI-1005, Sound CEO Jonathan Kil is keen to retain WuXi AppTec as a partner.

Marketing 246
article thumbnail

ICMR and Panacea Biotec initiate phase 3 clinical trial for the first indigenous dengue vaccine, DengiAll

AuroBlog - Aurous Healthcare Clinical Trials blog

The Indian Council of Medical Research (ICMR) and Panacea Biotec have announced the initiation of the first-ever phase 3 clinical trial for a dengue vaccine in India. The trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.

More Trending

article thumbnail

Novo plans new plant as it races to meet drug demand

Bio Pharma Dive

The new factory, which Novo is committing some $220 million to build, will supply raw materials for the company’s chronic disease medicines.

Medicine 162
article thumbnail

US govt taps Walgreens for decentralised trials

pharmaphorum

Walgreens has signed a $100m contract with the US government's BARDA agency for access to its decentralised clinical trials network

Trials 134
article thumbnail

FDA lifts partial hold on study of BioNTech-partnered ADC

Bio Pharma Dive

Partner MediLink Therapeutics is limiting the drug’s dosing after reports of lowered white blood cell counts and inflammation of the digestive tract.

Drugs 147
article thumbnail

Phanes acquires second FDA orphan designation for bispecific antibody

Pharmaceutical Technology

PT217 has received orphan drug designations from the FDA for the treatment of neuroendocrine carcinoma in addition to small cell lung cancer.

Antibody 130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Oncimmune announces new contract with global pharma company

Pharma Times

The contract concerns profiling Immunoglobulin E autoantibodies in blood serum

article thumbnail

US DoD grants $2.3m to Immuron for military version of anti-diarrhoeal Travelan

Pharmaceutical Technology

Immuron Limited has won a $2.3m grant to develop a version of its anti-diarrhoeal medication Travelan, following support from the US DoD.

article thumbnail

Nature publishes new research on genetic causes of colorectal cancer

Pharma Times

In the UK study, researchers analysed 2,023 bowel cancers from the 100,000 Genomes Project

article thumbnail

Overcoming common challenges in fill/finish for monoclonal antibodies (mAbs) 

Pharmaceutical Technology

According to GlobalData, annual biologic approvals outnumbering small molecules approvals is set to become a longstanding trend.

Antibody 130
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Genmab shuffles C-Suite on commercialization, manufacturing as portfolio grows

Fierce Pharma

Genmab is revamping its executive team as the Danish antibody specialist expands its commercialization efforts and looks to evolve into “a fully integrated biotech innovation powerhouse.” | Genmab is revamping its executive team as the Danish antibody specialist expands its commercialization efforts and looks to evolve into “a fully integrated biotech innovation powerhouse.

article thumbnail

Daiichi Sankyo-AstraZeneca’s ENHERTU gains BTD for breast cancer

Pharmaceutical Technology

Daiichi Sankyo and AstraZeneca's ENHERTU has received FDA BTD status for the treatment of specific types of metastatic breast cancer.

130
130
article thumbnail

Bavarian Nordic set to provide 12M doses of Jynneos to Africa amid current mpox outbreak

Fierce Pharma

With its rapid development of the Jynneos vaccine, Bavarian | After the WHO declared mpox a global health emergency for the second time in 25 months, Bavarian Nordic said it could ramp up manufacturing to supply 12 million doses of its Jynneos vaccine through 2025 to contain the virus in Africa.

article thumbnail

SciSparc and Polyrizon sign global agreement for pain therapy

Pharmaceutical Technology

SciSparc has signed an exclusive patent license agreement with Polyrizon to out-license its SCI-160 programme for pain treatment.

Licensing 130
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

FDA balks at standard approval of Liquidia's PAH rival to United's Tyvaso after lengthy court saga

Fierce Pharma

Liquidia and its dry powder Yutrepia is back in FDA limbo after the agency opted for a tentative approval as opposed to a standard nod. | The agency granted a broad regulatory exclusivity to rival United Therapeutics and its Tyvasvo DPI, leaving Liquidia's Yutrepia, which uses the same active drug, in FDA limbo until 2025.

Drugs 105
article thumbnail

Gilead partners with PANTHERx for LIVDELZI distribution

Pharmaceutical Technology

Gilead Sciences has partnered with PANTHERx Rare to distribute LIVDELZI, a primary biliary cholangitis (PBC) treatment.

130
130
article thumbnail

Were industry watchers too optimistic after IRA's price cut reveal? Analysts weigh in

Fierce Pharma

Industry watchers largely breathed a sigh of relief last week after the Medicare price cuts for certain costly drugs under the Inflation Reduction Act initially appeared better than expected. | The magnitude of price cuts under the Inflation Reduction Act initially appeared better than expected. However, that rosy view may have missed an important point, one analyst team contends.

Drugs 105
article thumbnail

Pfizer and BioNTech's COVID/flu vaccine hits a hurdle

pharmaphorum

Pfizer and BioNTech have a phase 3 mishap with their combined COVID-19 and influenza vaccine, handing Moderna an advantage

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Novo Financially Commits $220 Million Toward New Plant in Denmark

Pharmaceutical Commerce

The 86,000 square-foot Køge facility will be fully functional by 2027.

81
article thumbnail

Safeguarding patient data: Four steps to consider when assessing your IT infrastructure

pharmaphorum

Safeguarding patient data is crucial in the healthcare industry. This article outlines four steps to consider when assessing your IT infrastructure to protect against ransomware and ensure the security of patient data.

75
article thumbnail

How can Quality and Operations Teams Work Collaboratively to Drive Value for Clinical Trial Sponsors?

XTalks

The synergy between clinical trial quality and operations teams is vital for delivering value to sponsors. Effective collaboration between these teams can lead to smoother project execution and, ultimately, better outcomes for patients. However, achieving this level of coordination requires a deliberate and strategic approach grounded in transparency and mutual trust.

article thumbnail

EU starts review of Enhertu in HER2-ultra-low breast cancer

pharmaphorum

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER2 biomarker.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Which pharmaceutical companies have the most drug patents in Eurasian Patent Organization?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Eurasian Patent Organization.

Drugs 52
article thumbnail

EU starts review of Enhertu in HER2-ultralow breast cancer

pharmaphorum

EU starts review of Enhertu in HER2-ultralow breast cancer Phil.

64
article thumbnail

New tentative approval for Alembic drug dabigatran etexilate mesylate

Drug Patent Watch

Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.

Drugs 52
article thumbnail

After SPAC deal fell flat, Visiox acquired by fellow eye-focused biotech

Fierce Pharma

Eight months after Visiox Pharmaceuticals was all set to go public via a special purpose acquisition company (SPAC) deal, the company has been

52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.